Cervista HPV assays for fine-needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma
Ming Guo, Abha Khanna, Jasreman Dhillon, Shobha J. Patel, Jie Feng, Michelle D. Williams, Diana M. Bell, Yun Gong, Ruth L. Katz, Erich M. Sturgis and Gregg A. Staerkel
Article first published online: 11 DEC 2013 | DOI: 10.1002/cncy.21375
Sixty-four fine-needle aspiration (FNA) specimens from patients with head and neck squamous carcinoma are tested using the Cervista human papillomavirus type 16/18 (HPV16/18) assay and the Cervista HPV HR assay (for high-risk HPV types), and the results are compared with polymerase chain reaction-based HPV results from the same tissues and with HPV in situ hybridization assay/p16 immunostaining results from the corresponding primary tumors. The findings indicate that use of the Cervista HPV assays for testing head and neck FNA specimens is a valid option for determining HPV16/18 status in patients with oropharyngeal carcinoma.